World's Best Scientists 2026 revealed!
Giuseppe Saglio

Giuseppe Saglio

Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
120
Citations
74330
World Ranking
3676
National Ranking
106

Giuseppe Saglio publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Giuseppe Saglio sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,120 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Giuseppe Saglio D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Giuseppe Saglio sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 120 D-Index — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Giuseppe Saglio is affiliated with the University of Turin in Italy. Their research focuses primarily on the field of medicine, with particular expertise in hematology, genetics, and molecular biology. The scope of their work also includes rheumatology and public health, environmental, and occupational health.

The scientist's research extensively covers topics related to leukemia and related disorders. The main topics of their work include:

  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Eosinophilic Disorders and Syndromes
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Lymphoma Diagnosis and Treatment

Major publication venues where Giuseppe Saglio has contributed include:

  • Blood
  • Leukemia
  • Clinical Lymphoma Myeloma & Leukemia
  • Cancers
  • Journal of Clinical Medicine

Frequent collaborators in their research are:

  • Massimo Breccia
  • Carmen Fava
  • Monica Bocchia
  • Massimiliano Bonifacio
  • Giovanni Caocci

Notable recent publications by Giuseppe Saglio include:

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia, 2020, Leukemia
  • Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis, 2021, Leukemia
  • First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis, 2020, Blood Advances
  • Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors, 2020, Leukemia
  • Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial, 2021, Leukemia

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

    Brunangelo Falini;Christina Mecucci;Enrico Tiacci;Myriam Alcalay

  • Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

    J Gabert;E Beillard;V H J van der Velden;W Bi

  • Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

    Giuseppe Saglio;Dong-Wook Kim;Surapol Issaragrisil;Gabriel Etienne

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.

    van Dongen Jj;Macintyre Ea;Gabert Ja;Delabesse E

  • Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program

    E Beillard;N Pallisgaard;V H J van der Velden;W Bi

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

    Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford

  • Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

    Jorge E. Cortes;Giuseppe Saglio;Hagop M. Kantarjian;Michele Baccarani

  • Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

    A. Hochhaus;G. Saglio;Timothy Hughes;R. A. Larson

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

    Hagop M. Kantarjian;Andreas Hochhaus;Giuseppe Saglio;Carmino De Souza

  • PML targeting eradicates quiescent leukaemia-initiating cells

    Keisuke Ito;Rosa Bernardi;Alessandro Morotti;Sahoko Matsuoka

  • Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy

    Franco Mandelli;Daniela Diverio;Giuseppe Avvisati;Anna Luciano

  • Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

    Simona Soverini;Sabrina Colarossi;Alessandra Gnani;Gianantonio Rosti

Frequent Co-Authors

Giovanni Martinelli
Giovanni Martinelli University of Bologna
Michele Baccarani
Michele Baccarani University of Bologna
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Gianluca Gaidano
Gianluca Gaidano University of Eastern Piedmont Amadeo Avogadro
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Giorgina Specchia
Giorgina Specchia University of Bari Aldo Moro
Jerald P. Radich
Jerald P. Radich Fred Hutchinson Cancer Research Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Richard A. Larson
Richard A. Larson University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine offers diverse pathways, many of which can be started or advanced through online study. Online healthcare degrees provide flexibility for working adults and make it easier to take the next step in your medical career. Among the most popular choices are RN to BSN online programs, which help registered nurses earn their bachelor’s degree quickly and affordably from home.

For those seeking advanced practice roles, the cheapest online acute care nurse practitioner programs allow nurses to specialize in acute patient care without taking a break from their current job. Similarly, students balancing work and study may consider the cheapest rn to bsn online programs, which offer lower tuition rates and flexible schedules.

Professionals aiming for leadership or teaching positions can look into the cheapest online dnp programs for the doctoral-level expertise increasingly required in healthcare. Those just starting out, meanwhile, can fast-track their education by comparing reputable rn to bsn online programs. Investing in an online degree could be your first step toward a rewarding future in medicine.

Best Scientists Citing Giuseppe Saglio

Trending Scientists

Recently Published Articles